



# Hyperosmolar Hyperglycemic State: A Historic Review of the Clinical Presentation, Diagnosis, and Treatment

Francisco J. Pasquel and  
Guillermo E. Umpierrez

*Diabetes Care* 2014;37:3124–3131 | DOI: 10.2337/dc14-0984

The hyperosmolar hyperglycemic state (HHS) is the most serious acute hyperglycemic emergency in patients with type 2 diabetes. von Frerichs and Dreschfeld described the first cases of HHS in the 1880s in patients with an “unusual diabetic coma” characterized by severe hyperglycemia and glycosuria in the absence of Kussmaul breathing, with a fruity breath odor or positive acetone test in the urine. Current diagnostic HHS criteria include a plasma glucose level >600 mg/dL and increased effective plasma osmolality >320 mOsm/kg in the absence of ketoacidosis. The incidence of HHS is estimated to be <1% of hospital admissions of patients with diabetes. The reported mortality is between 10 and 20%, which is about 10 times higher than the mortality rate in patients with diabetic ketoacidosis (DKA). Despite the severity of this condition, no prospective, randomized studies have determined best treatment strategies in patients with HHS, and its management has largely been extrapolated from studies of patients with DKA. There are many unresolved questions that need to be addressed in prospective clinical trials regarding the pathogenesis and treatment of pediatric and adult patients with HHS.

The hyperosmolar hyperglycemic state (HHS) is a syndrome characterized by severe hyperglycemia, hyperosmolality, and dehydration in the absence of ketoacidosis. The exact incidence of HHS is not known, but it is estimated to account for <1% of hospital admissions in patients with diabetes (1). Most cases of HHS are seen in elderly patients with type 2 diabetes; however, it has also been reported in children and young adults (2). The overall mortality rate is estimated to be as high as 20%, which is about 10 times higher than the mortality in patients with diabetic ketoacidosis (DKA) (3–5). The prognosis is determined by the severity of dehydration, presence of comorbidities, and advanced age (4,6,7). Treatment of HHS is directed at replacing volume deficit and correcting hyperosmolality, hyperglycemia, and electrolyte disturbances, as well as management of the underlying illness that precipitated the metabolic decompensation. Low-dose insulin infusion protocols designed for treating DKA appear to be effective; however, no prospective randomized studies have determined best treatment strategies for the management of patients with HHS. Herein, we present an extensive review of the literature on diabetic coma and HHS to provide a historical perspective on the clinical presentation, diagnosis, and management of this serious complication of diabetes.

## History of Diabetic Coma and HHS

In 1828, in the textbook *Versuch einer Pathologie und Therapie des Diabetes Mellitus*, August W. von Stosch gave the first detailed clinical description of diabetic coma in an

*Division of Endocrinology, Department of Medicine, Emory University School of Medicine, Atlanta, GA*

Corresponding author: Guillermo E. Umpierrez, [geumpie@emory.edu](mailto:geumpie@emory.edu).

Received 18 April 2014 and accepted 6 July 2014.

© 2014 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.

adult patient with severe polydipsia, polyuria, and a large amount of glucose in the urine followed by progressive decline in mental status and death (8). Several case reports followed this publication, describing patients with newly diagnosed or previously known diabetes presenting with drowsiness or coma, most of them with a peculiar breath odor resembling acetone (9). In 1857, Petters (10) detected a substance in the urine of a fatal case of diabetic coma that resembled acetone in its reaction with sulfuric acid and caustic alkalis and was later recognized as acetoacetic acid, also called diacetic acid (11,12). Acetone was then recognized as an important outcome marker warning physicians about serious diseases, including diabetes (13,14). In 1874, Kussmaul reported several fatal cases of diabetic coma preceded and accompanied by severe dyspnea (15,16). Kussmaul breathing, as this condition came to be known, quickly became one of the hallmarks in the diagnosis of diabetic coma, along with the presence of positive urine ketones (14,17). In the 1880s, Stadelmann (18), Külz (19), and Minkowski (20) reported that the urine of most patients with diabetic coma contained, in addition to acetoacetic or diacetic acid, the presence of considerable quantities of  $\beta$ -oxybutyric acid (Table 1). The discovery of high concentrations of acetoacetic acid and  $\beta$ -hydroxybutyric acid led clinicians and researchers in the late 1890s to conclude that diabetic coma was a "self-intoxication" due to an excess of acids in the body (12,13).

The first reports of HHS are attributed to von Frerichs (21) and Dreschfeld (14). In the 1880s, they reported patients presenting with an unusual type of diabetic coma characterized by severe hyperglycemia and glycosuria but without Kussmaul breathing, fruity breath odor, or a positive urine acetone test. Dreschfeld (14) described a case series of patients with "diabetic collapse" presenting after age 40 years, who were well nourished at the time of the attack, and with fatty infiltration of the liver and the heart. Shortly after these reports, several authors (14,21) reported cases of diabetic coma in well-nourished adult patients with known diabetes, and the term "diabetes of stout people" was coined. In the early 1900s, others reported the presence of two distinct types

of patients with diabetic coma, noting that not all cases presented with the characteristic Kussmaul respiration or positive urine acetone or diacetic acid (22–26). These reports created confusion and were taken with skepticism, as the source of ketone bodies and the role of acetoacetic acid in the pathogenesis of diabetic coma were not known at the time. Many physicians were against accepting that adult patients could progress to diabetic coma in the absence of ketonuria. For example, in the 1930s, Elliot P. Joslin (17) and others (27) stated that the presence of acetone or diacetic acid in the urine was requisite for the diagnosis of diabetic coma. It was later hypothesized that diabetic coma with negative urinary ketones was the result of impaired renal excretion, liver dysfunction, and the presence of other acids, such as  $\beta$ -hydroxybutyric acid, rather than diacetic acid or acetone (25,26,28).

HHS syndrome received little attention and remained poorly understood until the reports by de Graeff and Lips (29) and Sament and Schwartz (30) in 1957. They reported that severe hyperglycemia resulted in osmotic diuresis, polyuria, and progressive water deficit. They discussed the relevance of measuring sodium and chloride levels to estimate extracellular hypertonicity and cellular dehydration, and they proposed that patients with severe hyperglycemia and diabetic coma should be treated with large quantities of water (29). Sament and Schwartz (30) suggested that some comatose patients with severe hyperglycemia and negative or trace ketonuria could be treated successfully with the administration of fluids and lower amounts of insulin compared with regular acidotic patients with diabetic coma.

#### Pathophysiology

HHS is characterized by extreme elevations in serum glucose concentrations and hyperosmolality without significant ketosis (Fig. 1). These metabolic derangements result from synergistic factors including insulin deficiency and increased levels of counterregulatory hormones (glucagon, catecholamines, cortisol, and growth hormone) (31–33). Hyperglycemia develops because of an increased gluconeogenesis and accelerated conversion of glycogen to glucose

(glycogenolysis) and by inadequate use of glucose by peripheral tissues, primarily muscle. From the quantitative standpoint, increased hepatic glucose production represents the major pathogenic disturbance responsible for hyperglycemia in DKA (34). As the glucose concentration and osmolality of extracellular fluid increase, an osmolar gradient is created that draws water out of the cells. Glomerular filtration is initially increased, which leads to glucosuria and osmotic diuresis. The initial glucosuria prevents the development of severe hyperglycemia as long as the glomerular filtration rate is normal. However, with continued osmotic diuresis, hypovolemia eventually occurs, which leads to a progressive decline in glomerular filtration rate and worsening hyperglycemia.

Higher hepatic and circulating insulin concentration as well as lower glucagon are present in HHS compared with patients with ketoacidosis (32,33). The higher circulating ratio of insulin/glucagon in patients with HHS prevents ketogenesis and the development of ketoacidosis. This concept is supported by clinical studies both in animals and in humans, which have shown that the half-maximal concentration of insulin for antilipolysis is lower than for glucose use by peripheral tissues (35). Finally, a direct role of hyperosmolality by inhibiting lipolysis and free fatty acid release from adipose tissue has been shown in experimental animals (36).

Severe hyperglycemia is associated with a severe inflammatory state characterized by an elevation of proinflammatory cytokines (tumor necrosis factor- $\alpha$ , interleukin (IL) $\beta$ , IL6, and IL8) and reactive oxygen species, with insulin secretion and action. Hyperglycemia causes an increase in oxidative stress markers such as membrane lipid peroxidation (37). The degree of lipid peroxidation is directly proportional to the glucose concentrations in diabetic patients. This is thought to occur via several well-studied mechanisms, including increased polyol pathway flux, increased intracellular formation of advanced glycation end products, activation of protein kinase C, or overproduction of superoxide by the mitochondrial electron transport chain (37,38). By interest, elevations of circulating proinflammatory cytokines are reduced to normal levels promptly




Figure 1—Pathogenesis of HHS.

in response to insulin therapy and normalization of blood glucose concentration (39).

**Precipitating Factors**

HHS occurs most commonly in elderly patients with type 2 diabetes. Infection represents the commonest precipitating

cause of HHS in essentially all series and occurs in 40–60% of patients, with the most common precipitating infections being pneumonia (40–60%) and urinary tract infection (5–16%) (40–42). Up to 20% do not have a previous diagnosis of diabetes (7). Underlying medical illness, such as stroke, myocardial infarction,

and trauma, that provokes the release of counterregulatory hormones and/or compromises the access to water can result in severe dehydration and HHS. In most patients, restricted water intake is due to the patient being bedridden or restrained and is exacerbated by the altered thirst response of the elderly. Certain

Table 1—From diabetic coma to HHS

Years	Authors (reference nos.)	Comment
1828	von Stosch (8)	Initial descriptions of diabetic coma
1857	Peters (10)	Discovery of acetone in the urine of patients with diabetes
1865	Gerhardt (91)	Discovery of acetoacetic acid in the urine of patients with diabetes
1874	Kussmaul (15)	First extensive description of diabetic coma
1878	Foster (11)	Cases of diabetic coma and acetonemia
1883–1884	Stadelmann (18)/Külz (19)/Minkowski (20)	Discovery of β-hydroxybutyric acid in patients with diabetes
1884–1886	von Frerichs (21)/Dreschfeld (14)	Description of a nonketotic diabetic coma
1922	Banting et al. (83)	Insulin discovery
1909–1923	Lépine (92)/Revillet (93)/McCaskey (94)/Bock et al. (95)	Case series of diabetic coma without ketonuria
1930–1935	Lawrence (84)/Joslin (17)	Initial recommendations for the management of diabetic comas
1957	Sament and Schwartz (30)/de Graeff and Lips (29)	Detailed case reports of diabetic coma without ketones and hyperosmolality
1962	Singer et al. (85)	Linking osmolality and hyperglycemia
1971	Arieff and Carroll (55)/Gerich et al. (54)	Case series of HHS; initial criteria
1973	Arieff and Kleeman (77)	Mechanisms leading to cerebral edema
1976–1977	Alberti and Hockaday (60)/Kitabchi et al. (70)	Low-dose insulin protocols
2004–2009	Kitabchi et al. (4,86,87)	Position Statement, American Diabetes Association: management of hyperglycemic crises
2011	Zeitler et al. (59)	Guidelines for the management of HHS in children

medications associated with metabolic decompensation and HHS include glucocorticoid, thiazide diuretics, phenytoin,  $\beta$ -blockers, and more recently atypical antipsychotics (43–49).

Recent case reports and series suggest an increasing incidence of this disorder in children and adolescents (50,51). In children, most common precipitating causes are diseases of the circulatory, nervous, and genitourinary systems (52). In addition, some children with T1DM may present with features of HHS (severe hyperglycemia) if high-carbohydrate-containing beverages have been used to quench thirst and replace urinary losses prior to diagnosis (53).

### Diagnostic Criteria of HHS

The modern definition and diagnostic criteria of HHS derived from case series reported by Gerich et al. (54) and Arieff and Carroll (55) in 1971 (Table 2). They also provided insights into the pathophysiology of the syndrome they called “hyperglycemic hyperosmolar nonketotic coma” (HHNK). Arieff and Carroll’s diagnostic criteria included a blood glucose level  $>600$  mg/dL, a total serum osmolality level  $>350$  mOsm/L, and a serum acetone reaction from 0 to 2 pluses when the serum was diluted 1:1 with water (55). The selection of a glucose concentration  $>600$  mg/dL was based on the observation that above this level, serum osmolality is  $>350$  mOsm/kg (56). Arieff and Carroll also reported that patients with HHNK coma had a mean plasma osmolality of  $\sim 380$  mOsm/L, compared with the  $\sim 320$ – $330$  mOsm/L osmolality observed in conscious patients (54,55,57). In addition, they reported that patients with HHNK coma had an admission

plasma bicarbonate level of  $17.0 \pm 6$  mEq/L, a mean arterial pH of 7.31, and an average plasma glucose level of  $1,076 \pm 350$  mg/dL (range 650–1,780 mg/100 mL). Current diagnostic criteria of HHS recommended by the American Diabetes Association (ADA) and international guidelines include a plasma glucose level  $>600$  mg/dL, plasma effective osmolality  $>320$  mOsm/L, and an absence of significant ketoacidosis (Table 2) (4,58,59). The term HHNK was replaced with “hyperglycemic hyperosmolar state” to reflect the fact that many patients present without significant decline in the level of consciousness (less than one-third of patients present with coma) and because many patients can present with mild to moderate degrees of ketosis (32,60). In some studies, up to 20% of patients with severe hyperglycemia and hyperosmolality were reported to have combined features of HHS and DKA (7,32).

In contrast with the original formula proposed by Arieff and Carroll (55) to estimate total serum osmolality [ $2(\text{Na}) + 18/\text{glucose} + \text{BUN}/2$ ], recent reports and consensus guidelines have recommended the use of effective serum osmolality [ $2(\text{Na}) + 18/\text{glucose}$ ] not taking into consideration urea, as the osmotic contribution of urea is not significant compared with the effects of sodium and glucose levels (32,61,62). Urea is distributed equally in all body compartments, and its accumulation does not induce an osmotic gradient across the cell membranes. Symptoms of encephalopathy are usually present when serum sodium levels exceed 160 mEq/L and when the calculated total and effective

osmolality are  $>340$  and 320 mOsm/kg, respectively (32,63).

### Evolution of HHS treatment

In the 19th century and preinsulin era, a large number of treatment modalities were recommended to treat diabetic coma. Kussmaul tried blood transfusions with only temporary results. Reynolds (64) published two cases of recovery with castor oil followed by 63 grains of citrate of potassium. In the late 1900s, the most common therapeutic regimen was the administration of subcutaneous and intravenous saline solutions with 3% sodium carbonate (13). Chadbourne (65) reported that among 17 cases of diabetic coma, only one case was treated successfully, and seven patients showed a temporary improvement in consciousness.

Before the discovery of insulin, diabetic coma was regarded as an inevitable culmination of life, as it was exceedingly rare for a diabetic individual to live for more than a few months after an episode of diabetic coma (17). After the discovery of insulin in 1922, the development of diabetic coma became much less frequent in patients with diabetes, and when acquired, patients had better treatment options. After the 1930s,  $<10\%$  of hospital admissions for diabetes were due to diabetic coma (17).

Shortly after the introduction of insulin, patients with diabetic coma were treated with 20–100 units s.c. soluble insulin every 30 min on a sliding scale according to the Benedict test for glucosuria (17). The total insulin dose for treatment of diabetic coma was increased in the 1940s after the reports by Root (66) and Black and Malins (67), who recommended an initial bolus dose

**Table 2—Diagnostic criteria of HHS first reported by Arieff and Carroll and current ADA criteria**

	Arieff and Carroll (56)	ADA (4)
Plasma glucose, mg/dL	$>600$	$>600$
Arterial pH	N/A	$>7.30$
Serum bicarbonate, mEq/L	N/A	$>18$
Urine or serum ketones by nitroprussiate test (acetoacetate)	0 to 2 pluses	Negative or small
Serum $\beta$ -hydroxybutyrate, mmol/L	N/A	$<3$ mmol/L
Total serum osmolality, mOsm/kg*	$>350$	N/A
Effective serum osmolality, mOsm/L**	N/A	$>320$
Anion gap, mEq/L	N/A	Variable
Mental status	N/A	Variable; most patients present with stupor, coma

\*Total serum osmolality formula =  $2(\text{Na}) + 18/\text{glucose} + \text{BUN}/2$ . \*\*Effective serum osmolality formula =  $2(\text{Na}) + 18/\text{glucose}$ .

of 200–400 units i.v. soluble insulin depending on the severity of the mental status. Three arbitrary stages were used to guide initial bolus doses: stage 1, drowsy but easily rousable; stage 2, rousable with difficulty; and stage 3, unconscious on admission. These researchers suggested giving an initial injection of 200 units to patients in stage 1, 300 units to patients in stage 2, and 400 units to patients in stage 3, followed by boluses of 50 units i.v. injected into drip tubing every 30 min until the urine became free of acetone bodies (67). From 1950 to the 1970s, most experts in the field recommended an initial bolus dose of 20–80 units intramuscularly (i.m.) or i.v. followed by 20–80 units i.m. or i.v. every 1–2 h (68). It was recognized that patients with HHS required lower doses of insulin than patients with DKA, who were given ~50–100 units i.m. or i.v. every hour (68).

In 1973, Alberti et al. (69) were the first to report the successful treatment of patients with diabetic coma using small intramuscular doses of regular insulin. They treated 14 patients with ketoacidosis, one patient with hyperosmolar nonketotic coma, and two cases of hyperglycemic nonketotic state with an initial mean dose of  $16 \pm 2$  units followed by 5 or 10 units i.v. or i.m. every hour. The patients' plasma glucose rates fell at a regular rate of 90 mg/h (69). The authors reported a cumulative insulin dose of <100 units per day, which was a significant reduction from previous reports that used 400–500 units per day. These studies were later confirmed by two randomized, controlled trials conducted by Kitabchi and colleagues (70,71), who compared treatment using low-dose intramuscular with treatment using large-dose intravenous and subcutaneous regular insulin (Table 3). Unfortunately, no prospective, randomized

studies have been conducted in patients with HHS, and those patients are treated following the protocols designed to treat DKA. Low-dose insulin infusion protocols have been shown to be effective, with resolution of hyperglycemia in  $\sim 9 \pm 2$  h and resolution of HHS in  $11 \pm 1$  h (7).

The importance of hydration and electrolyte replacement has been recognized in the management of patients with HHS (32,72). Isotonic saline (0.9% NaCl) is recommended at 15–20 mL/kg during the first 1–2 h, followed by 250–500 mL/h until resolution of the hyperglycemic crisis. Fluid replacement alone has been shown to reduce glucose concentration by 75–100 mg/h, due to a reduction in counterregulatory hormones and improvement of renal perfusion (73). In addition, many patients with HHS have high serum potassium despite total body potassium deficit due to insulin deficiency and hyperosmolality,

**Table 3—Evolution of treatment regimens for patients with diabetic coma and HHS**

Years (reference nos.)	Insulin therapy	Fluids	Other
Preinsulin era (13,14)	—	NS/3% NS (s.c.)	Alcohol, laxatives, alkalies, salicylate, oxygen inhalations, castor oil and citrate of potassium, camphor and ether, caffeine, circulatory stimulants
1930–1950 (17,27)	20–100 units i.v. or s.c. bolus followed by 20 units s.c. every 30–60 min depending on glucosuria	NS (s.c. or i.v.) at variable rates	Routine gastric lavage, cleansing enema, blood transfusion
1950–1970s (29,88,89)	2 units/kg bolus of crystalline insulin; up to 920 units in the first 7 h	NS followed by hypotonic solution $\sim 30$ mL/kg or 600–800 cc $\times$ m <sup>2</sup>	Gastric aspiration
Early 1970s (54,68,90)	50 units i.v. bolus followed by 50–80 units/h i.v. or s.c.	NS at 1–1.5 L over the first 2 h, followed by hypotonic solution at $\sim 100$ mL/h	Add 20 mEq potassium to the second or third liter of fluid when potassium level is <6.0 mEq/L
Late 1970s (60,71)	Low-dose insulin regimens. Regular insulin 0.1 units/kg i.v. followed by 0.1–0.3 units/h i.v., s.c., or i.m.	NS at 1–2 L over the first 2 h, followed by NS or half NS. Add dextrose-containing solutions when glucose $\sim 250$ mg/dL	Risk of hypokalemia during insulin treatment identified. Early potassium replacement when serum potassium <5.5 mEq/L
1990s (7)	0.1 units/kg i.v. bolus, then 0.1 units/kg/h as continuous infusion until glucose level <13.8 mmol/L (250 mg/dL)	0.9% saline, 500–1,000 mL/h for 2 h, then switch to 0.45% saline at 250–500 mL/h. Add dextrose-containing solutions when glucose $\sim 250$ mg/dL	No gastric lavage or gastric suction recommended
2004–2009 (4,87): ADA consensus for treatment of DKA and HHS in adult patients	Initial bolus (0.1 units/kg i.v.), followed by 0.1 units/kg/h until glucose <250 mg/dL, then reduce insulin by 50%	NS at 500–1,000 mL/h for 2–4 h, then 0.45% saline at 250–500 mL/h	
2011 (59): Pediatric Endocrine Society guidelines for treatment of HHS in children	In HHS: no intravenous insulin bolus, start at 0.025–0.05 units/kg/h when no decline in glucose with fluids alone; in hyperosmolar DKA: start 0.05–0.1 units/kg/h	20 mL/kg NS bolus until adequate tissue perfusion	Dantrolene*

NS, normal saline (0.9% NaCl). \*If a malignant hyperthermia-like syndrome is suspected.



which cause a shift of potassium from the intracellular compartment into plasma (74,75). During insulin treatment and hydration, serum potassium levels rapidly fall; therefore, it is recommended that potassium replacement should be initiated when serum levels fall <5.5 mEq/L, with the goal to maintain a serum potassium concentration in the range of 4–5 mEq/L.

Arief and colleagues (56,76,77) first reported the development of brain edema, a feared complication of treatment after rapid correction of hyperglycemia and hyperosmolality. They reported that cerebral edema developed during diabetic coma treatment after a rapid lowering of plasma glucose levels in nondiabetic animals. Hyperglycemia was induced by infusing 50% glucose to maintain the plasma glucose level at ~60 mmol/L (1,080 mg/dL) for periods of 1–4 h. After 4 h of hyperglycemia, brain osmolality (343 mOsm/kg H<sub>2</sub>O) was similar to that of cerebrospinal fluid (340 mOsm/kg). The authors proposed that during glucose infusion and the development of extracellular hyperosmolality, the brain protects against changes in volume by increasing osmolality, largely through a gain in unidentified solutes (idiogenic osmoles). They also observed that rapid normalization of plasma glucose due to insulin and hypotonic fluid administration resulted in gross brain edema as a result of an osmotic gradient between brain and plasma (77). Although such observations have not been demonstrated in humans, it is believed that rapid changes in plasma and brain osmolality after the administration of hypotonic fluids could result in brain edema. Thus, it is recommended that glucose levels be kept at ~300 mg/dL when managing patients with HHS in order to prevent brain edema (68,77).

#### Future Areas of Research

Several unresolved questions regarding the pathogenesis and treatment of HHS in adults and children need to be addressed in prospective clinical trials.

A major question is the cause of the lack of ketosis in HHS patients compared with DKA patients. Some studies have indicated that HHS patients have higher circulating insulin concentration levels, sufficient to prevent lipolysis and generation of ketone bodies; however, levels

of free fatty acids and counterregulatory hormones are comparable between patients with DKA and HHS. Additional studies are also needed to determine the role of inflammatory and oxidative stress markers and clinical outcomes in patients with hyperglycemic crises. Elucidating the roles of these pathways might provide valuable information for reducing the high cardiovascular and thrombotic morbidity rates associated with hyperglycemic emergencies.

Hospitalizations for HHS in children and adolescents have increased significantly in recent reports. Population rates for HHS hospitalizations in children between 1997 and 2009 increased by 52.4%, with a reported yearly increase of 4.4% (52). Clinical programs are needed for early detection and management to reduce the development of hyperglycemic crises in the pediatric population.

The frequency and pathogenesis of cerebral edema in adults and children with HHS needs to be determined in well-designed prospective studies. Similarly, prospective studies are needed to settle the long-term controversy regarding the use of anticoagulant therapy in patients with hyperglycemic crises. Several case reports have indicated an increased risk of thrombosis, which is greater in HHS than in ketoacidosis (78,79). Severe dehydration and hypertonicity may result in osmotic disruption of endothelial cells, leading to a release of tissue thromboplastins and elevated vasopressin caused by the fluid status, which may contribute to enhanced coagulation (80). However, uncomplicated diabetes has never been shown to be an independent risk factor for venous thromboembolism (81). In a retrospective review of 426,831 cases of venous thromboembolism, the overall incidence among patients with hyperosmolality was 1.7%, which is only modestly lower than the incidence in patients undergoing orthopedic surgery (82). The risk benefit of anticoagulation therapy in patients with HHS and DKA has not been evaluated prospectively.

The most recent ADA Position Statement on the management of hyperglycemic crises in adult patients proposed a single treatment algorithm for the management of DKA and HHS. Low-dose insulin infusion protocols for treating DKA appear to be effective, but the mortality rate is about 10 times higher in HHS

patients than in DKA patients (5,7). Thus, prospective studies are needed to determine effective and safe insulin and hydration strategies, as well as to determine glucose targets during intravenous insulin infusion and during the transition to subcutaneous insulin therapy in patients with HHS.

**Duality of Interest.** No potential conflicts of interest relevant to this article were reported.

**Author Contributions.** F.J.P. reviewed the literature and drafted the manuscript. G.E.U. critically reviewed and revised the manuscript.

#### References

1. Fishbein HA, Palumbo PJ. Acute metabolic complications in diabetes. In *Diabetes in America*. National Diabetes Data Group, National Institutes of Health, 1995, p. 283–291 (NIH publ. no. 95-1468)
2. Rosenbloom AL. Hyperglycemic hyperosmolar state: an emerging pediatric problem. *J Pediatr* 2010;156:180–184
3. Milionis HJ, Elisaf MS. Therapeutic management of hyperglycaemic hyperosmolar syndrome. *Expert Opin Pharmacother* 2005;6:1841–1849
4. Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN. Hyperglycemic crises in adult patients with diabetes. *Diabetes Care* 2009;32:1335–1343
5. Fadini GP, de Kreutzenberg SV, Rigato M, et al. Characteristics and outcomes of the hyperglycemic hyperosmolar non-ketotic syndrome in a cohort of 51 consecutive cases at a single center. *Diabetes Res Clin Pract* 2011;94:172–179
6. Wachtel TJ, Silliman RA, Lamberton P. Prognostic factors in the diabetic hyperosmolar state. *J Am Geriatr Soc* 1987;35:737–741
7. Umpierrez GE, Kelly JP, Navarrete JE, Casals MM, Kitabchi AE. Hyperglycemic crises in urban blacks. *Arch Intern Med* 1997;157:669–675
8. von Stosch A. *Versuch einer Pathologie und Therapie des Diabetes Mellitus*. Berlin, Duncker und Humblot, 1828 [in German]
9. Warburg E. Some cases of diabetic coma complicated with uraemia, and some remarks on the previous history of the diabetic coma. *Acta Med Scand* 1925;61:301–334
10. Petters W. Untersuchungen über die Honigharnruhr. *Vrtljschr Prakt Heilk* 1857;3:81–94 [in German]
11. Foster B. Diabetic coma: acetonaemia. *BMJ* 1878;1:78–81
12. Munson EL. The chemistry of the urine in diabetes mellitus. *J Am Med Assoc* 1897;28:831–836
13. Fitcher T. Diabetic coma, aetiology, symptoms, and treatment. *North NY Med J* 1897;66:821–825
14. Dreschfeld J. The Bradshaw Lecture on Diabetic Coma. *BMJ* 1886;2:358–363
15. Kussmaul A. Zur lehre vom diabetes mellitus. *Dtsch Arch Klin Med* 1874;14:1–46 [in German]
16. Adolf Kussmaul (1822-1902)—country doctor to clinical professor. *JAMA* 1964;189:58–59
17. Joslin E. *The Treatment of Diabetes Mellitus*. 5th ed. Philadelphia, Lea & Febiger, 1935, p. 302–323

18. Stadelmann E. Ueber die Ursachen der pathologischen ammoniakausscheidung beim diabetes mellitus und des coma diabeticum. *Arch Exp Pathol und Pharmakol* 1883;17:419–444 [in German]
19. Külz E. Ueber eine neue linksdrehende saure (pseudo-oxybuttersäure). *Zeitschr f Biologie* 1884;20:165–178 [in German]
20. Minkowski O. Ueber das vorkommen von oxybuttersäure im harn bei diabetes mellitus. *Arch Exp Pathol und Pharmakol* 1884;18:35–48 [in German]
21. von Frerichs F. Über den diabetes, Berlin. August Hirschwald 1884;1884:113 [in German]
22. Rosenbloom J. A form of diabetic coma, not due to the acetone bodies. *New York M. J.* 1915; 102:294–296
23. Starr P, Fitz R. The excretion of organic acids in the urine of patients with diabetes mellitus. *Arch Intern Med* 1924;33:97–108
24. Labbe M, Boulin R, Labbe M, Boulin R. Coma diabetique sans reaction de Gerhardt. *Bull Mem Soc Med Paris* 1933;49:313
25. Marble A, Root H, White P. Diabetic coma. *N Engl J Med* 1935;212:288–297
26. Root HF, Leech R. Diabetic coma and hyperglycemic stupor compared. *Med Clin North Am* 1946;30:1115–1130
27. John HJ. Treatment of diabetic coma: clinical lecture at Atlantic City session. *J Am Med Assoc* 1935;105:587–592
28. Martin HE, Wick AN. Quantitative relationships between blood and urine ketone levels in diabetic ketosis. *J Clin Invest* 1943;22:235–241
29. de Graeff J, Lips JB. Hypernatraemia in diabetes mellitus. *Acta Med Scand* 1957;157:71–75
30. Sament S, Schwartz MB. Severe diabetic stupor without ketosis. *S Afr Med J* 1957;31: 893–894
31. Macaulay MB. Hyperosmolar non-ketotic diabetes. *Postgrad Med J* 1971;47:191–196
32. Kitabchi AE, Umpierrez GE, Murphy MB, et al. Management of hyperglycemic crises in patients with diabetes. *Diabetes Care* 2001;24: 131–153
33. Chupin M, Charbonnel B, Chupin F. C-peptide blood levels in keto-acidosis and in hyperosmolar non-ketotic diabetic coma. *Acta Diabetol Lat* 1981;18:123–128
34. Luzi L, Barrett EJ, Groop LC, Ferrannini E, DeFronzo RA. Metabolic effects of low-dose insulin therapy on glucose metabolism in diabetic ketoacidosis. *Diabetes* 1988;37:1470–1477
35. Miles JM, Haymond MW, Nissen SL, Gerich JE. Effects of free fatty acid availability, glucagon excess, and insulin deficiency on ketone body production in postabsorptive man. *J Clin Invest* 1983;71:1554–1561
36. Gerich J, Penhos JC, Gutman RA, Recant L. Effect of dehydration and hyperosmolarity on glucose, free fatty acid and ketone body metabolism in the rat. *Diabetes* 1973;22:264–271
37. Rains JL, Jain SK. Oxidative stress, insulin signaling, and diabetes. *Free Radic Biol Med* 2011;50:567–575
38. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. *Nature* 2001;414:813–820
39. Stentz FB, Umpierrez GE, Cuervo R, Kitabchi AE. Proinflammatory cytokines, markers of cardiovascular risks, oxidative stress, and lipid peroxidation in patients with hyperglycemic crises. *Diabetes* 2004;53:2079–2086
40. Wachtel TJ. The diabetic hyperosmolar state. *Clin Geriatr Med* 1990;6:797–806
41. Wachtel TJ, Tetu-Mouradjian LM, Goldman DL, Ellis SE, O'Sullivan PS. Hyperosmolarity and acidosis in diabetes mellitus: a three-year experience in Rhode Island. *J Gen Intern Med* 1991;6: 495–502
42. Kitabchi AE, Wall BM. Diabetic ketoacidosis. *Med Clin North Am* 1995;79:9–37
43. Lorber D. Nonketotic hypertonicity in diabetes mellitus. *Med Clin North Am* 1995;79:39–52
44. Kitabchi AE, Fisher JN, Murphy MB, Rumbak MJ. Diabetic ketoacidosis and the hyperglycemic hyperosmolar nonketotic state. In *Joslin's Diabetes Mellitus*. 13th ed. Kahn CR, Weir GC, Eds. Philadelphia, Lea & Febiger, 1994, p. 738–770
45. Ananth J, Parameswaran S, Gunatilake S. Side effects of atypical antipsychotic drugs. *Curr Pharm Des* 2004;10:2219–2229
46. Tavakoli SA, Arguisola MS. Diabetic ketoacidosis in a patient treated with olanzapine, valproic acid, and venlafaxine. *South Med J* 2003; 96:729–730
47. Wilson DR, D'Souza L, Sarkar N, Newton M, Hammond C. New-onset diabetes and ketoacidosis with atypical antipsychotics. *Schizophr Res* 2003;59:1–6
48. Ekpebegh C, Longo-Mbenza B. Mortality in hyperglycemic crisis: a high association with infections and cerebrovascular disease. *Minerva Endocrinol* 2013;38:187–193
49. Roefaro J, Mukherjee SM. Olanzapine-Induced hyperglycemic nonketonic coma. *Ann Pharmacother* 2001;35:300–302
50. Canarie MF, Bogue CW, Banasiak KJ, Weinzimer SA, Tamborlane WV. Decompensated hyperglycemic hyperosmolarity without significant ketoacidosis in the adolescent and young adult population. *J Pediatr Endocrinol Metab* 2007;20:1115–1124
51. Fourtner SH, Weinzimer SA, Levitt Katz LE. Hyperglycemic hyperosmolar non-ketotic syndrome in children with type 2 diabetes. *Pediatr Diabetes* 2005;6:129–135
52. Bagdure D, Rewers A, Campagna E, Sills MR. Epidemiology of hyperglycemic hyperosmolar syndrome in children hospitalized in USA. *Pediatr Diabetes* 2013;14:18–24
53. McDonnell CM, Pedreira CC, Vadamalayan B, Cameron FJ, Werther GA. Diabetic ketoacidosis, hyperosmolarity and hypernatremia: are high-carbohydrate drinks worsening initial presentation? *Pediatr Diabetes* 2005;6:90–94
54. Gerich JE, Martin MM, Recant L. Clinical and metabolic characteristics of hyperosmolar nonketotic coma. *Diabetes* 1971;20:228–238
55. Arieff AI, Carroll HJ. Hyperosmolar nonketotic coma with hyperglycemia: abnormalities of lipid and carbohydrate metabolism. *Metabolism* 1971;20:529–538
56. Arieff AI, Carroll HJ. Nonketotic hyperosmolar coma with hyperglycemia: clinical features, pathophysiology, renal function, acid-base balance, plasma-cerebrospinal fluid equilibria and the effects of therapy in 37 cases. *Medicine (Baltimore)* 1972;51:73–94
57. Fulop M, Tannenbaum H, Dreyer N. Ketotic hyperosmolar coma. *Lancet* 1973;2:635–639
58. Park BE, Meacham WF, Netsky MG. Nonketotic hyperglycemic hyperosmolar coma. Report of neurosurgical cases with a review of mechanisms and treatment. *J Neurosurg* 1976; 44:409–417
59. Zeitler P, Haqq A, Rosenbloom A, Glaser N; Drugs and Therapeutics Committee of the Lawson Wilkins Pediatric Endocrine Society. Hyperglycemic hyperosmolar syndrome in children: pathophysiological considerations and suggested guidelines for treatment. *J Pediatr* 2011;158: 9–14
60. Alberti KG, Hockaday TD. Diabetic coma: a reappraisal after five years. *Clin Endocrinol Metab* 1977;6:421–455
61. Poser CM. Hyperglycemic non-ketotic coma. Role of sodium in the pathogenesis of the neurologic manifestations. *Dis Nerv Syst* 1972;33:725–729
62. Feig PU, McCurdy DK. The hypertonic state. *N Engl J Med* 1977;297:1444–1454
63. Gershengorn HB, Iwashyna TJ, Cooke CR, Scales DC, Kahn JM, Wunsch H. Variation in use of intensive care for adults with diabetic ketoacidosis. *Crit Care Med* 2012;40:2009–2015
64. Reynolds ES. On the treatment of diabetic coma. *Med Chron* 1891;14:338–340
65. Chadbourne AP. A case of diabetic coma, treated by intravenous injection of saline solution; death. *Boston Med Surg J* 1890;122:623–625
66. Root H. The use of insulin and the abuse of glucose in the treatment of diabetic coma. *JAMA* 1945;127:557–563
67. Black AB, Malins JM. Diabetic ketosis; a comparison of results of orthodox and intensive methods of treatment based on 170 consecutive cases. *Lancet* 1949;1:56–59
68. Hockaday TD, Alberti KG. Diabetic coma. *Clin Endocrinol Metab* 1972;1:751–788
69. Alberti KG, Hockaday TD, Turner RC. Small doses of intramuscular insulin in the treatment of diabetic "coma." *Lancet* 1973;2:515–522
70. Kitabchi AE, Ayyagari V, Guerra SM. The efficacy of low-dose versus conventional therapy of insulin for treatment of diabetic ketoacidosis. *Ann Intern Med* 1976;84:633–638
71. Fisher JN, Shahshahani MN, Kitabchi AE. Diabetic ketoacidosis: low-dose insulin therapy by various routes. *N Engl J Med* 1977;297:238–241
72. Waldhäusl W, Kleinberger G, Korn A, Dudczak R, Bratusch-Marrain P, Nowotny P. Severe hyperglycemia: effects of rehydration on endocrine derangements and blood glucose concentration. *Diabetes* 1979;28:577–584
73. Matz R. Management of the hyperosmolar hyperglycemic syndrome. *Am Fam Physician* 1999;60:1468–1476
74. Cruz-Caudillo JC, Sabatini S. Diabetic hyperosmolar syndrome. *Nephron* 1995;69:201–210
75. Ennis ED, Stahl EJVB, Kreisberg RA. The hyperosmolar hyperglycemic syndrome. *Diabetes Rev* 1994;2:115–126
76. Arieff AI. Cerebral edema complicating nonketotic hyperosmolar coma. *Miner Electrolyte Metab* 1986;12:383–389
77. Arieff AI, Kleeman CR. Studies on mechanisms of cerebral edema in diabetic comas. Effects of hyperglycemia and rapid lowering of plasma glucose in normal rabbits. *J Clin Invest* 1973;52:571–583

78. Halmos PB, Nelson JK, Lowry RC. Hyperosmolar non-ketoacidotic coma in diabetes. *Lancet* 1966;1:675–679
79. Tripodi A, Branchi A, Chantarangkul V, et al. Hypercoagulability in patients with type 2 diabetes mellitus detected by a thrombin generation assay. *J Thromb Thrombolysis* 2011;31:165–172
80. Grant PJ, Tate GM, Hughes JR, Davies JA, Prentice CR. Does hypernatraemia promote thrombosis? *Thromb Res* 1985;40:393–399
81. Heit JA, Leibson CL, Ashrani AA, Petterson TM, Bailey KR, Melton LJ 3rd. Is diabetes mellitus an independent risk factor for venous thromboembolism?: a population-based case-control study. *Arterioscler Thromb Vasc Biol* 2009;29:1399–1405
82. Keenan CR, Murin S, White RH. High risk for venous thromboembolism in diabetics with hyperosmolar state: comparison with other acute medical illnesses. *J Thromb Haemost* 2007;5:1185–1190
83. Banting FG, Best CH, Collip JB, Campbell WR, Fletcher AA. Pancreatic extracts in the treatment of diabetes mellitus. *Can Med Assoc J* 1922;12:141–146
84. Lawrence RD. The treatment of desperate cases of diabetic coma. *BMJ* 1930;1:690–692
85. Singer DL, Drolette ME, Hurwitz D, Freinkel N. Serum osmolality and glucose in maturity onset diabetes mellitus. *Arch Intern Med* 1962;110:758–762
86. Kitabchi AE, Umpierrez GE, Fisher JN, Murphy MB, Stentz FB. Thirty years of personal experience in hyperglycemic crises: diabetic ketoacidosis and hyperglycemic hyperosmolar state. *J Clin Endocrinol Metab* 2008;93:1541–1552
87. Kitabchi AE, Umpierrez GE, Murphy MB, et al.; American Diabetes Association. Hyperglycemic crises in diabetes. *Diabetes Care* 2004;27 (Suppl. 1):S94–S102
88. Butler AM. Diabetic coma. *N Engl J Med* 1950;243:648–659
89. Lucas CP, Grant N, Daily WJ, Reaven GM. Diabetic coma without ketoacidosis. *Lancet* 1963;1:75–77
90. Alstead S, Macgregor AG, Girdwood RH, Dunlop DM. *Textbook of Medical Treatment*. Edinburgh, Churchill Livingstone, 1971
91. Gerhardt J. Diabetes mellitus und acetone. *Wien Med Presse* 1865;6:672 [in German]
92. Lépine R. *Le Diabète Sucré*. Alcan F, Ed. Paris, Ancienne Librairie Germer Baillière et Cie, 1909 [in French]
93. Revillet J. Coma chez une diabétique sans acétonurie. *Lyon Med* 1914;122:817 [in French]
94. McCaskey G. A case of fatal diabetic coma without diacetic or beta-oxybutyric acid. *JAMA* 1916;66:350–351
95. Bock A, Field Jr H, Adair G. The acid-base equilibrium in diabetic coma, being a study of five cases treated with insulin. *J Metab Res* 1923;4:27